Showing results (201-210 of 379) with videos related to
Sort By:
Pageof 38
European Radiology|May 1, 2025
Adverse effects of systemic advanced melanoma therapies-do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis?Marcel Alexander Drews, Alexander Baumgarten, Sebastian Zensen, et al.Plos One|April 22, 2015
Corticosteroids augment BRAF inhibitor vemurafenib induced lymphopenia and risk of infectionWiebke Sondermann, Klaus G Griewank, Bastian Schilling, et al.European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisCindy Franklin, Isabelle Rooms, Melanie Fiedler, et al.Frontiers in Oncology|September 12, 2022
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion ratesGeorg C Lodde, Melanie Fiedler, Ulf Dittmer, et al.European Journal of Cancer (Oxford, England : 1990)|August 12, 2019
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaTheodora Kanaki, Andreas Stang, Ralf Gutzmer, et al.ESC Heart Failure|July 27, 2022
Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapyJulia Pohl, Matthias Totzeck, Raluca-I Mincu, et al.Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 14, 2013
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasKlaus G Griewank, Bastian Schilling, Rajmohan Murali, et al.Cardio-Oncology (London, England)|June 17, 2026
Cardiac dysfunction during immune checkpoint inhibitor therapy: association with extracardiac immune-related adverse eventsRaluca I Mincu, Lena Lampe, Lars Michel, et al.Pageof 38